nucleotides guanine

A compound being developed to treat Friedreich's ataxia specifically targets an unwanted molecular brake

posted on September 30, 2009 - 1:28pm
Scientists at the Scripps Research Institute in La Jolla, Calif., and the Repligen Corporation in Waltham, Mass., have identified the precise biochemical brake that limits production of a needed protein in Friedreich's ataxia (FA) and determined that this brake is specifically targeted by an experimental compound being developed to treat this disease. MDA is supporting Repligen to develop this...

New content is being added every day. Please check back again.